PreludeDx™ Announces the Appointment of Derek J. Maetzold of Castle Biosciences to its Board of Directors

LAGUNA HILLS, Calif.: LAGUNA HILLS, Calif., Feb. 2, 2022 /PRNewswire/ — Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that it has appointed Derek J. Maetzold, Founder, President and Chief Executive Officer of Castle Biosciences, Inc. to the Company’s Board of…